deltatrials
Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06008249

Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)

A Multi-arm, Adaptive, Group-sequential Trial NETwork to Evaluate Drug Efficacy in Patients With Amyotrophic Lateral Sclerosis (ALS)

Sponsor: Alan Davidson Foundation

Updated 4 times since 2023 Last updated: Jun 6, 2025 Started: Aug 9, 2021 Primary completion: Jun 30, 2026 Completion: Jun 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06008249, this PHASE3 trial focuses on Amyotrophic Lateral Sclerosis and remains actively recruiting participants. Sponsored by Alan Davidson Foundation, it has been updated 4 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshotRecruiting~Jul 2025 – present · 13 months · monthly snapshotRecruiting

Change History

4 versions recorded
  1. Jul 2025 — Present [monthly]

    Recruiting PHASE3

  2. Sep 2024 — Jul 2025 [monthly]

    Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  4. Sep 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

    First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alan Davidson Foundation
  • Fight MND
  • Luzon Foundation
  • MNDA
  • My name'5 Doddie Foundation
  • Research Foundation Flanders
  • Stichting ALS Nederland
  • Stichting TRICALS Foundation
  • Thierry Latran Foundation
  • Ulla-Carin Lindquist Foundation
Data source: Stichting TRICALS Foundation

For direct contact, visit the study record on ClinicalTrials.gov .